Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand?
Mené sur 375 patients atteints d'un adénocarcinome canalaire du pancréas (durée médiane de suivi : 42,3 mois ; 44 % de femmes), cet essai randomisé multicentrique de phase III évalue l'efficacité, du point de vue de la survie globale, d'un traitement néoadjuvant de type FOLFIRINOX par rapport à une chimioradiothérapie néoadjuvante à base de gemcitabine
Pancreatic cancer is a growing global health concern, with rising incidence rates, particularly in Europe and North America. At diagnosis, only 10–20% of patients present with localised disease amenable to surgery, which remains essential for any curative approach. However, due to the high rate of occult micrometastases—present in more than 90% of apparently localised cases—systemic therapy is also required.
The Lancet Oncology , commentaire, 2025